IcICLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Trial Overview and Summary

IcICLLe looks at the mechanism of action of ibrutinib. Ibrutinib has been tested previously in clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL) patients, but the way it works is still unknown. This initial phase is fully recruited.

The aim of the IcICLLe Extension Study is to investigate the effectiveness and safety of ibrutinib used in combination with obinutuzumab in patients with CLL who are relapsed/refractory.  The trial may also give us information about how using both of the drugs together affects the rate of growth, and the lifespan, of leukaemia cells.

New patients can only register to the Extension Study.

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator: Professor Peter Hillmen 
Sponsor:  University of Birmingham
Funders:  TAP Bloodwise
Disease Site:  Chronic Lymphocytic Leukaemia
Trial Type:  Clinical Trial of an Investigational Medicinial Product
Status:  Open
UKCRN Study ID: (if applicable)  15429
Open to new sites?  No
Recruitment start date:  12 June 2014
Anticipated Recruitment end date  31 January 2017
CRCTU Trial Management Team:  Haematology
Trial E-mail Address:  IcICLLe@trials.bham.ac.uk

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More Information